Vanessa Mirsky Email & Phone Number

Portland, Or, Us

Nashville, Tennessee, Us

Lead the data monetization strategy for OneOncology's Data Solutions business that leverages a robust set of EHR data across OneOncology's network of practices. Bring together Clinical, Data & Analytics and Corporate Strategy to deliver data-driven insights through execution of RWD/RWE projects in partnership with life sciences companies.

Zug, Zug, Ch

Advised commercial team of a digital market access platform on global payer partnerships, HTA facilitation, and access contracts

Reporting to the office of the CEO, led the commercial international payer partnerships team in the execution of first-of-their kind collaborations in support of EQRx's corporate mission and vision. Executed first population health partnership in cancer with NHS England in the UK.

Co-led the execution of the first innovative US payer partnership for EQRx with a large regional payer, supporting a proof point for the viability of the EQRx commercial model

Williamstown, Massachusetts, Us

Responsible for business development to grow the healthcare software business. Developed the strategy and led the execution, increasing annual revenues by 30% and expanding into new markets globally.

Fleet, Hampshire, Gb

Led global commercialization strategy engagements (US, EU5 and emerging markets) to develop foundational P&R and pricing strategy to support commercialization of early and late stage assets across a breadth of orphan and non-orphan therapeutic areas spanning oncology, infectious disease and autoimmune. PRMA Consulting was acquired by Fishawack, which became Avalere.Sample Engagements:Go/No-Go Decision Support for a Phase 2 renal disease drug based on P&R/market access opportunities and risk assessment in the US and EU5.Recent Oncology P&R Landscape Trends in the US and EU5 across 9 scope products, including a mix of orphan drugs and non-orphan drugs, comparing first-to-market vs. later launch reimbursement outcomes, and learnings from manufacturers who both succeeded and failed in satisfying reimbursement authorities.HTA Analysis in Inflammatory Bowel Disease (Crohn’s disease and ulcerative colitis) to critically understand the P&R landscape for marketed drugs, including infliximab, adalimumab, certolizumab pegol, and golimumab.Emerging Markets Opportunity Assessment for an HCV asset in Phase 1 development which resulted in identifying the top 5 emerging markets, based on key clinical and economic factors.

Freelance Commercialization strategy consulting to support clinical development and market launch activities for pharmaceutical, biotech, medical device companies. Sample Engagements:Oncology Managed Care Contracting Strategy – Assessed the potential of contracting, determined the optimal approach for managing varied customers needs, and characterized the opportunity at large cancer centers for an anti-emetic therapy.Oncology Early Stage Clinical Development Strategy – Completed market assessment due diligence on colorectal and renal cancer tumor types, including current and pipeline competitor analysis, clinical development hurdles, unmet needs, and near-term future trends in managed care and healthcare policy, to determine appropriate clinical development paths for two Phase I compounds.

Worldwide, Oo

Led HEOR change management initiative led by C-suite executives at a large, global pharmaceutical manufacturer. US commercialization expert informing private equity due diligence engagements across biotech and device companies.Sample Engagements:Private Equity Acquisition Due Diligence – Executed a financial due diligence engagement on behalf of a private equity client interested in acquiring a medical device spin-off from a large healthcare supply company.Health Outcomes Group Reorganization – Developed strategic recommendations to improve organizational structure and function of the Health Outcomes group within a mid-tier pharmaceutical company, in order to prioritize health outcomes in clinical development planning such that reimbursement feasibility becomes a key consideration in go/no-go decisions.Targeted Therapeutics White Paper – Contributed to a white paper outlining the health economic impact of targeted therapeutics, including how to optimize formulary placement and UM strategies with payers.

New York, Ny, Us

De facto US reimbursement and market access expert across auto-immune, oncology and primary care therapeutic areas. One of first two employees to join the firm at its inception. Insight was acquired by Precision Value & Health.Sample Engagements:Patient Flow Analysis – Created a clinical developmnt. opp. assessment through analysis of medical/pharmacy patient claims data, which led to a set of clinical developmnt opportunities for an early stage compound Medical Director Assessment – Provided strategies on how to influence HMO/PBM MDRs to secure initial formulary positioning, defend positioning, and prevent restrictionsPayer Risk Assessment – Led a robust analysis of payer “willingness” to absorb risk for a lifestyle therapy in order to provide Managed Markets team with a list of targeted payer accounts for Contracting OpsBrand Planning – Facilitated strategic brand planning for a late stage biologic with the goal of aligning functional areas within the brand and address potential market barriersDevice Commercial Opportunity Assessment – Identified market capture opps. for two home-use cardiac monitor devices based on epidemiology of target pops., consumer price sensitivity, and reimbursement

Quantitative and qualitative analysis to support venture capital due diligence (Series C financing) and leading US payer reimbursement and market access consulting projects servicing a diverse range of biotech and pharmaceutical clients

Payor/Provider Consulting; PARC; Hospital revenue cycle management; IT contracts management systems

Washington, District Of Columbia, Us

Payor/Provider & Hospital Benchmarking Research

Master Of Arts - Ma (Mapss Program), Social Sciences

Bachelor Of Arts - Ba, Psychology (Pre-Medicine Minor), Cum Laude